Meeting
2019 Gastrointestinal Cancers Symposium
CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer.
Authors
Hagen F. Kennecke
Virginia Mason Hospital and Medical Center, Seattle, WA
Hagen F. Kennecke , Carl J Brown , Rebecca Auer , Sebastien Drolet , Cathy Eng , Vallerie Lynn Gordon , David J Hochman , Hussein Moloo , Alice C Wei , Kelvin Chan , Alexander Montenegro , Jonathan M. Loree , Dongsheng Tu , Derek J. Jonker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT03259035
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS724)
DOI
10.1200/JCO.2019.37.4_suppl.TPS724
Abstract #
TPS724
Poster Bd #
Q9
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial.
First Author: Jonathan M. Loree
Poster
2024 ASCO Annual Meeting
Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial.
First Author: Weizhong Jiang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TnT) with FOLFOX followed by short course radiation in locally advanced rectal cancer: A phase II study.
First Author: Janice Zhao
Poster
2023 ASCO Annual Meeting
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
First Author: Salvatore Siena